2026-04-13T00:49:37Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/77402024-12-13T09:32:58Zcom_2072_378070com_2072_378040col_2072_378092

Unmasking New Promises: Expanding the Antigen Landscape For Antibody–Drug Conjugates Kumar Oberoi, Honey Garralda Cabanas, Elena Institut Català de la Salut Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain Vall d'Hebron Barcelona Hospital Campus Càncer - Tractament Medicaments - Alliberament retardat Anticossos monoclonals - Ús terapèutic DISEASES::Neoplasms Other subheadings::Other subheadings::Other subheadings::/drug therapy CHEMICALS AND DRUGS::Pharmaceutical Preparations::Prodrugs CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Serum Globulins::Immunoglobulins::Antibodies::Immunoconjugates ENFERMEDADES::neoplasias Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia COMPUESTOS QUÍMICOS Y DROGAS::preparados farmacéuticos::profármacos COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::globulinas séricas::inmunoglobulinas::anticuerpos::inmunoconjugados Antibody–Drug Conjugates; Cancer treatment Conjugats anticossos-fàrmacs; Tractament contra el càncer Conjugados anticuerpo-fármaco; Tratamiento contra el cáncer Cross-reactivity with normal tissues is one of the key concerns for target selection for antibody–drug conjugates. Probody therapeutics are masked antibodies that can selectively be activated by proteases in the tumor. CX-2029, is a first-in-class Probody targeting CD71 with preliminary efficacy and a tolerable safety profile 2022-06-28T10:40:27Z 2022-06-28T10:40:27Z 2021-08-15 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Oberoi HK, Garralda E. Unmasking new promises: expanding the antigen landscape for antibody drug conjugates. Clin Cancer Res. 2021 Aug 15;27(16):4459–61. 1557-3265 https://hdl.handle.net/11351/7740 10.1158/1078-0432.CCR-21-1353 34135020 000753846600001 http://hdl.handle.net/11351/7740 eng Clinical Cancer Research;27(16) https://doi.org/10.1158/1078-0432.CCR-21-1353 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess application/pdf American Association for Cancer Research Scientia